Developer docs
API playgroundTry for free, no card

Search company profiles

iZafe

Full company profile

uuid0005e8p

Namestring
iZafe
Legal namestring
iZafe Group AB
Websiteurl
izafe.se
Company typeenum
Public
Founded yearint
2008
Descriptiontext

iZafe Group AB is a Swedish MedTech company founded in 2008 and listed on Nasdaq First North Growth Market since 2018, headquartered in Stockholm with a team of approximately 10 employees. The company develops and markets digital medication management solutions centered on two core products: Dosell, a patented medication dispensing robot that automatically releases tablets in dose bags at prescribed times, issues reminders, and alerts caregivers when doses are missed; and Pilloxa, a SaaS platform with a connected smart pillbox acquired in November 2022 and aimed at pharmaceutical companies running clinical studies. A modular external Display add-on and a remote care platform were launched in Q1 2026, extending Dosell's reach to patients with cognitive impairment and enabling remote monitoring by healthcare providers.

The business model is pure recurring license revenue with no hardware sales; Annual Recurring Revenue (ARR) reached approximately 10 MSEK at the beginning of 2026, up 488% from approximately 1.7 MSEK a year earlier, and management is guiding to roughly 22.5 MSEK by year-end 2026. Q4 2025 net sales of 2,435 TSEK consisted entirely of recurring license revenue. Customers are concentrated in the public sector — Swedish municipalities and regions via the Adda national framework, regional procurements such as Region Jönköping (framework value up to SEK 82.5 million), and partner-served municipal deals in Norway, Iceland, and the Netherlands — alongside pharmaceutical companies using Pilloxa for clinical trials. Go-to-market is predominantly channel-driven through distribution partners (Adda, Atea Sverige AB, Vakt og Alarm AS, Skand ehf) and inclusion on national programs such as the Dutch Digizo.nu, supported by participation in healthcare exhibitions such as Vitalis and WHX Dubai. The company holds European patent EP4228584 for sensor-data-driven medication adjustment and has obtained ISO/IEC 27001 certification across the Group, both of which strengthen its position in public-sector tenders and cross-border expansion.

Short descriptiontext

iZafe Group AB is a Swedish MedTech company that develops the Dosell medication dispensing robot and Pilloxa SaaS platform, serving municipalities, healthcare providers, and pharmaceutical companies across the Nordics and selected European markets via a recurring license model.

Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersStockholm, Sweden
HQ citystring
Stockholm
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital medication management, medication dispensing systems, medication adherence technology, clinical trial software, e-health solutions
Industry4 codes
PRIMARYHLALAIAG
Medication Adherence & Therapy Management Platforms (refills, reminders, MTM)
Healthcare & Life Sciences/Telehealth Platforms/Pharmacy-Integrated Telehealth & ePrescribing Platforms
SECONDARYHSABALAI
Remote Adherence Monitoring & Smart Dispenser Services
Home & Personal Services/Elder Care & In-Home Care Services/Medication Management & In-Home Pharmacy Support
SECONDARYHLACAPAH
Medication Adherence & Smart Drug Delivery (Connected Inhalers, Pens, Pill Dispensers)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLACAKAH
Medication Therapy Management (MTM) & Clinical Pharmacy Services Tools
Healthcare & Life Sciences/Digital Health & Health IT/ePrescribing, Medication Management & Pharmacy IT
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Services-Prepackaged Software7372
Product category
Digital Medication Management
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Recurring License Revenues
TypeSubscription Recurring
Description

iZafe Group generates revenue entirely from recurring license revenues with no hardware sales, marking a full transition from a hardware-dominated revenue model to a subscription-based business model. The company's annual recurring revenue (ARR) reached approximately 10 MSEK at the beginning of 2026, representing 488% year-over-year growth, with forecasts projecting ARR to reach 22.5 MSEK by year-end 2026.

morningstar.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
Pricing details1 tier
1Subscription-based recurring revenue model with license fees
ModelSubscriptionBilling cadenceAnnual
Notes

Revenue generated entirely from recurring license revenues. No hardware sales. Annual Recurring Revenue (ARR) reached approximately 10 MSEK at beginning of 2026.

morningstar.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

iZafe Group AB develops and markets digital medication management solutions, led by Dosell — a patented medication dispensing robot that automatically dispenses tablets in dose bags at prescribed times, reminds patients when medication is due, and alerts caregivers when doses are missed. Through its wholly-owned subsidiary Pilloxa AB, the company also offers a SaaS platform with a connected smart pillbox for clinical trial patient engagement and real-time insights.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Annual Recurring Revenue grew from approximately 1.7 MSEK at beginning of 2025 to approximately 10 MSEK at beginning of 2026, representing 488% year-over-year growth
+3 more records
Product overview1 text field

iZafe Group offers a portfolio of digital medication management solutions built around two core products: Dosell, a patented medication dispensing robot that automates tablet dispensing and alerts caregivers to missed doses, and Pilloxa, a SaaS platform with smart pillbox technology for clinical studies. The company operates a subscription-based (SaaS) business model. The product portfolio also includes a modular external Display add-on and a remote care system, both launched in 2026 to expand Dosell's functionality for patients with cognitive impairment and enable remote monitoring by healthcare providers. All solutions are designed to reduce medication errors, increase adherence, and support safer medication management at home.

Product and service4 records
1Dosell Medication Dispensing Robot
CategoryMedication Dispensing Hardware-as-a-Service
Description

Patented medication dispensing robot for safer medication in the home and in elderly care residences. Automatically dispenses tablets in dose bags at prescribed times, reminds patients when medication is due, and alerts care staff when medication is missed. Reduces the risk of overdose, incorrect drug combinations, and missed medications.

2Pilloxa Clinical Study Platform
CategoryClinical Trial SaaS Platform
Description

SaaS solution and smart pillbox for clinical studies that provides real-time patient insights and improves data quality. Engages and involves patients throughout studies with an innovative digital platform supporting pharmaceutical companies and clinical trial operations.

3Dosell Modular External Display
CategoryMedication Dispensing Add-on
Description

Modular external display solution designed to extend Dosell medication dispenser functionality to patients with cognitive impairment or those requiring additional visual guidance, broadening the target group and increasing value per installed unit.

4Dosell Remote Care System
CategoryRemote Care SaaS Platform
Description

Remote care platform that complements the Dosell medication dispenser by enabling healthcare providers to monitor medication adherence and patient status remotely, supporting proactive care and remote healthcare delivery.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1Region Jönköping County and its Municipalities
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-04-01
Description

Dosell AB was awarded a sub-contract by Region Jönköping County and its municipalities for medication dispensing systems as part of a coordinated regional procurement. The framework agreement, effective April 1, 2026, runs for an initial two-year period with potential extension up to four years. The total estimated procurement value is approximately SEK 55 million with a maximum ceiling of SEK 82.5 million.

pharmiweb.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-04-01
Description

Dosell AB selected as solution in procurement where Atea Sverige AB awarded agreement with Västerviks kommun and samverkande kommuner for delivery of medication dispensing robots. Agreement effective April 1, 2026, covering approximately 500 units representing approximately SEK 3.7 million in annual recurring revenue at full rollout.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-03-31
Description

Dosell AB signed framework agreement with Adda Inköpscentral following the conclusion of the appeal period for Sweden's first national procurement of medication dispensing robots. The agreement enters into force on March 31, 2026, enabling municipalities and regions across Sweden to procure Dosell through Adda's purchasing system via call-offs under the framework.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-01-01
Description

Approval for inclusion on the Dutch Digizo.nu national program, enabling broader market access in the Netherlands for healthcare technology solutions.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-11-20
Description

iZafe Group signed distribution agreement with Skand ehf to launch and sell the medication dispensing robot Dosell in Iceland. The initial order includes 300 units, with scheduled delivery in 2026, and is expected to generate SEK 2-3 million annually.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-01-01
Description

Distribution partnership with Vakt og Alarm AS for Norway, including joint win of public procurement covering six Norwegian municipalities. Implementation began February 1 with approximately 100 units.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Digital medication management platform that helps patients and caregivers manage medications, reminders, and refills. Comparable in the medication-adherence software/consumer-app layer of iZafe's Pilloxa offering.

TypeDirect peer
Description

Finnish-headquartered provider of automated medication dispensing robots and remote monitoring services for home care, with an established Nordic municipal customer base. Evondos is the closest head-to-head competitor to Dosell in automated dose-bag dispensers for elderly home care.

TypeEmerging player
Description

Health companion robot that engages patients at home with medication reminders and adherence support. Overlaps with Dosell's reminder and caregiver-alert functionality, although the form factor and patient profile differ.

4Pillo Health
TypeEmerging player
Description

Voice-activated medication management and adherence device for the home, integrated with caregiver apps. Comparable to the modular Display and remote care system aspects of Dosell, although focused on a different interaction modality.

TypeDirect peer
Description

US-based connected medication management device that sorts and dispenses pills and tracks adherence, sold as a subscription to households. Direct functional comparable to Dosell on automated home dispensing and adherence monitoring.

TypeBroad incumbent
Description

Global medical technology company offering medication management solutions (including BD Pyxis and home infusion products). Overlaps with Dosell in medication safety, dispensing, and adherence, and is a potential strategic acquirer or competitor in European home care.

7AdhereTech
TypeDirect peer
Description

Connected smart pill bottle and adherence analytics platform deployed primarily in clinical trials and specialty pharmacy programs. Comparable to the Pilloxa side of iZafe's portfolio, where connected packaging is paired with real-time adherence data.

TypeBroad incumbent
Description

Philips Lifeline offers a medication dispenser service for seniors, bundled with its broader remote patient monitoring and personal emergency response portfolio. While not a dose-bag robot, it competes for the same municipal and home-care procurement budgets for medication adherence.

TypeBroad incumbent
Description

Large US-listed provider of medication management solutions for hospitals, pharmacies, and home care, including automated dispensing and adherence tools. Competes indirectly for healthcare-provider medication-management budgets and could expand downstream into home dispensing.

TypeDirect peer
Description

US-based smart pill dispenser provider serving elderly and chronic-disease patients at home, with remote monitoring and adherence alerts for caregivers. Comparable in product form factor and recurring service model to Dosell.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

iZafe

Digital Medication Managementizafe.se

iZafe Group AB is a Swedish MedTech company that develops the Dosell medication dispensing robot and Pilloxa SaaS platform, serving municipalities, healthcare providers, and pharmaceutical companies across the Nordics and selected European markets via a recurring license model.

What iZafe does

iZafe Group AB is a Swedish MedTech company founded in 2008 and listed on Nasdaq First North Growth Market since 2018, headquartered in Stockholm with a team of approximately 10 employees. The company develops and markets digital medication management solutions centered on two core products: Dosell, a patented medication dispensing robot that automatically releases tablets in dose bags at prescribed times, issues reminders, and alerts caregivers when doses are missed; and Pilloxa, a SaaS platform with a connected smart pillbox acquired in November 2022 and aimed at pharmaceutical companies running clinical studies. A modular external Display add-on and a remote care platform were launched in Q1 2026, extending Dosell's reach to patients with cognitive impairment and enabling remote monitoring by healthcare providers.

The business model is pure recurring license revenue with no hardware sales; Annual Recurring Revenue (ARR) reached approximately 10 MSEK at the beginning of 2026, up 488% from approximately 1.7 MSEK a year earlier, and management is guiding to roughly 22.5 MSEK by year-end 2026. Q4 2025 net sales of 2,435 TSEK consisted entirely of recurring license revenue. Customers are concentrated in the public sector — Swedish municipalities and regions via the Adda national framework, regional procurements such as Region Jönköping (framework value up to SEK 82.5 million), and partner-served municipal deals in Norway, Iceland, and the Netherlands — alongside pharmaceutical companies using Pilloxa for clinical trials. Go-to-market is predominantly channel-driven through distribution partners (Adda, Atea Sverige AB, Vakt og Alarm AS, Skand ehf) and inclusion on national programs such as the Dutch Digizo.nu, supported by participation in healthcare exhibitions such as Vitalis and WHX Dubai. The company holds European patent EP4228584 for sensor-data-driven medication adjustment and has obtained ISO/IEC 27001 certification across the Group, both of which strengthen its position in public-sector tenders and cross-border expansion.

iZafe firmographics

Firmographics
Name
iZafe
Legal name
iZafe Group AB
Website
https://izafe.se
Company type
Public
Founded year
2008
Headcount range
1–10 employees
Short description
iZafe Group AB is a Swedish MedTech company that develops the Dosell medication dispensing robot and Pilloxa SaaS platform, serving municipalities, healthcare providers, and pharmaceutical companies across the Nordics and selected European markets via a recurring license model.
Ownership category
akta.pro rank

iZafe industry classification

Industry
Product category
Digital Medication Management
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLALAIAG
Medication Adherence & Therapy Management Platforms (refills, reminders, MTM)
Healthcare & Life Sciences/Telehealth Platforms/Pharmacy-Integrated Telehealth & ePrescribing Platforms
SECONDARYHSABALAI
Remote Adherence Monitoring & Smart Dispenser Services
Home & Personal Services/Elder Care & In-Home Care Services/Medication Management & In-Home Pharmacy Support
SECONDARYHLACAPAH
Medication Adherence & Smart Drug Delivery (Connected Inhalers, Pens, Pill Dispensers)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLACAKAH
Medication Therapy Management (MTM) & Clinical Pharmacy Services Tools
Healthcare & Life Sciences/Digital Health & Health IT/ePrescribing, Medication Management & Pharmacy IT

Keywords

  • Digital medication management
  • Medication dispensing systems
  • Medication adherence technology
  • Clinical trial software
  • E-health solutions

Where iZafe is headquartered

Location

Headquarters

HQ city
Stockholm
HQ country
Sweden
HQ region
Europe

Offices1 record

Markets served

iZafe business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Recurring License Revenues: iZafe Group generates revenue entirely from recurring license revenues with no hardware sales, marking a full transition from a hardware-dominated revenue model to a subscription-based business model. The company's annual recurring revenue (ARR) reached approximately 10 MSEK at the beginning of 2026, representing 488% year-over-year growth, with forecasts projecting ARR to reach 22.5 MSEK by year-end 2026.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualSubscription-based recurring revenue model with license fees

Go-to-market motion1 record

Distribution channels5 records

Marketing channels4 records

iZafe product offering

Product offering

Core offering

iZafe Group AB develops and markets digital medication management solutions, led by Dosell — a patented medication dispensing robot that automatically dispenses tablets in dose bags at prescribed times, reminds patients when medication is due, and alerts caregivers when doses are missed. Through its wholly-owned subsidiary Pilloxa AB, the company also offers a SaaS platform with a connected smart pillbox for clinical trial patient engagement and real-time insights.

Product overview

iZafe Group offers a portfolio of digital medication management solutions built around two core products: Dosell, a patented medication dispensing robot that automates tablet dispensing and alerts caregivers to missed doses, and Pilloxa, a SaaS platform with smart pillbox technology for clinical studies. The company operates a subscription-based (SaaS) business model. The product portfolio also includes a modular external Display add-on and a remote care system, both launched in 2026 to expand Dosell's functionality for patients with cognitive impairment and enable remote monitoring by healthcare providers. All solutions are designed to reduce medication errors, increase adherence, and support safer medication management at home.

Differentiator

Problem solved

Functional benefit

Products and services

  • Dosell Medication Dispensing Robot Patented medication dispensing robot for safer medication in the home and in elderly care residences. Automatically dispenses tablets in dose bags at prescribed times, reminds patients when medication is due, and alerts care staff when medication is missed. Reduces the risk of overdose, incorrect drug combinations, and missed medications.
  • Pilloxa Clinical Study Platform SaaS solution and smart pillbox for clinical studies that provides real-time patient insights and improves data quality. Engages and involves patients throughout studies with an innovative digital platform supporting pharmaceutical companies and clinical trial operations.
  • Dosell Modular External Display Modular external display solution designed to extend Dosell medication dispenser functionality to patients with cognitive impairment or those requiring additional visual guidance, broadening the target group and increasing value per installed unit.
  • Dosell Remote Care System Remote care platform that complements the Dosell medication dispenser by enabling healthcare providers to monitor medication adherence and patient status remotely, supporting proactive care and remote healthcare delivery.

Quantifiable outcome

  • Annual Recurring Revenue grew from approximately 1.7 MSEK at beginning of 2025 to approximately 10 MSEK at beginning of 2026, representing 488% year-over-year growth
  • +3 more outcomes

Companies that use iZafe

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles2 records

iZafe technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

iZafe partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • Region Jönköping County and its MunicipalitiescoreChannel Partner/ Reseller/ Distributor · 1 April 2026Dosell AB was awarded a sub-contract by Region Jönköping County and its municipalities for medication dispensing systems as part of a coordinated regional procurement. The framework agreement, effective April 1, 2026, runs for an initial two-year period with potential extension up to four years. The total estimated procurement value is approximately SEK 55 million with a maximum ceiling of SEK 82.5 million.
  • Atea Sverige ABcoreChannel Partner/ Reseller/ Distributor · 1 April 2026Dosell AB selected as solution in procurement where Atea Sverige AB awarded agreement with Västerviks kommun and samverkande kommuner for delivery of medication dispensing robots. Agreement effective April 1, 2026, covering approximately 500 units representing approximately SEK 3.7 million in annual recurring revenue at full rollout.
  • Adda Inköpscentral (ADDA)coreChannel Partner/ Reseller/ Distributor · 31 March 2026Dosell AB signed framework agreement with Adda Inköpscentral following the conclusion of the appeal period for Sweden's first national procurement of medication dispensing robots. The agreement enters into force on March 31, 2026, enabling municipalities and regions across Sweden to procure Dosell through Adda's purchasing system via call-offs under the framework.
  • Digizo.numinorChannel Partner/ Reseller/ Distributor · 1 January 2026Approval for inclusion on the Dutch Digizo.nu national program, enabling broader market access in the Netherlands for healthcare technology solutions.
  • Skand ehfcoreChannel Partner/ Reseller/ Distributor · 20 November 2025iZafe Group signed distribution agreement with Skand ehf to launch and sell the medication dispensing robot Dosell in Iceland. The initial order includes 300 units, with scheduled delivery in 2026, and is expected to generate SEK 2-3 million annually.
  • Vakt og Alarm AScoreChannel Partner/ Reseller/ Distributor · 1 January 2025Distribution partnership with Vakt og Alarm AS for Norway, including joint win of public procurement covering six Norwegian municipalities. Implementation began February 1 with approximately 100 units.

Scale indicators10 records

Recent moves7 records

Expansion highlights7 records

iZafe competitors and assessment

Company assessment

Emerging players

  • CareZone: Digital medication management platform that helps patients and caregivers manage medications, reminders, and refills. Comparable in the medication-adherence software/consumer-app layer of iZafe's Pilloxa offering.
  • Catalia Health: Health companion robot that engages patients at home with medication reminders and adherence support. Overlaps with Dosell's reminder and caregiver-alert functionality, although the form factor and patient profile differ.
  • Pillo Health: Voice-activated medication management and adherence device for the home, integrated with caregiver apps. Comparable to the modular Display and remote care system aspects of Dosell, although focused on a different interaction modality.

Direct peers

  • Evondos: Finnish-headquartered provider of automated medication dispensing robots and remote monitoring services for home care, with an established Nordic municipal customer base. Evondos is the closest head-to-head competitor to Dosell in automated dose-bag dispensers for elderly home care.
  • Hero Health: US-based connected medication management device that sorts and dispenses pills and tracks adherence, sold as a subscription to households. Direct functional comparable to Dosell on automated home dispensing and adherence monitoring.
  • AdhereTech: Connected smart pill bottle and adherence analytics platform deployed primarily in clinical trials and specialty pharmacy programs. Comparable to the Pilloxa side of iZafe's portfolio, where connected packaging is paired with real-time adherence data.
  • MedMinder: US-based smart pill dispenser provider serving elderly and chronic-disease patients at home, with remote monitoring and adherence alerts for caregivers. Comparable in product form factor and recurring service model to Dosell.

Broad incumbents

  • BD (Becton Dickinson): Global medical technology company offering medication management solutions (including BD Pyxis and home infusion products). Overlaps with Dosell in medication safety, dispensing, and adherence, and is a potential strategic acquirer or competitor in European home care.
  • Philips Medication Dispensing Service: Philips Lifeline offers a medication dispenser service for seniors, bundled with its broader remote patient monitoring and personal emergency response portfolio. While not a dose-bag robot, it competes for the same municipal and home-care procurement budgets for medication adherence.
  • Omnicell: Large US-listed provider of medication management solutions for hospitals, pharmacies, and home care, including automated dispensing and adherence tools. Competes indirectly for healthcare-provider medication-management budgets and could expand downstream into home dispensing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

iZafe compliance and trust

Trust signal

Compliance2 records

iZafe financial estimates

Financial estimate

Revenue estimate

Valuation estimate

iZafe leadership team

Management profile

Number of profiles

Profiles9 records

iZafe subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

iZafe funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

iZafe M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about iZafe

What does iZafe do?

iZafe Group AB develops and markets digital medication management solutions, led by Dosell — a patented medication dispensing robot that automatically dispenses tablets in dose bags at prescribed times, reminds patients when medication is due, and alerts caregivers when doses are missed. Through its wholly-owned subsidiary Pilloxa AB, the company also offers a SaaS platform with a connected smart pillbox for clinical trial patient engagement and real-time insights.

Is iZafe a public or private company?

iZafe is a public company. It is classified as public.

When was iZafe founded?

iZafe was founded in 2008. It employs 1 to 10 people.

Where is iZafe based?

iZafe is headquartered in Stockholm, Sweden, in the Europe region.

How does iZafe make money?

One revenue line is on record: recurring License Revenues.

Who are iZafe's main competitors?

Emerging players on record are CareZone, Catalia Health and Pillo Health. Direct peers are Evondos, Hero Health, AdhereTech and MedMinder. Broad incumbents are BD (Becton Dickinson), Philips Medication Dispensing Service and Omnicell.

Does iZafe have an API?

No public API is recorded for iZafe.

What industry is iZafe in?

iZafe's product category is Digital Medication Management. Its primary akta.pro industry code is HLALAIAG, Medication Adherence & Therapy Management Platforms (refills, reminders, MTM), with a secondary code of HSABALAI, Remote Adherence Monitoring & Smart Dispenser Services. Its NAICS code is 325412 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Dagens industriIzafes rörelseförlust ökar – sänker intäktsprognosIzafe Group reported net revenue of 1.8 million SEK for the third quarter of 2026, up from 1.1 million SEK in the prior period. The increase is explained by the inclusion of the Dutch business in consolidated figures. The company has cut its revenue forecast.Dagens industriIzafe står fast vid prognos trots ökad förlustIzafe reported net revenue of 2.6 million Swedish kronor for the second quarter of 2026, up from 1.1 million. CEO Anders Segerström said the company will stick to its forecast despite the loss. The company develops digital medical solutions for home medication management.Dagens industriIzafe gör kvittningsemissionIzafe, a company developing digital medical solutions for medication management at home, has decided on a directed offset issue of approximately 10.3 million shares at a subscription price of 0.33 kronor per share. The capital raise was announced on July 31, 2026. Anders Segerström serves as CEO of the company.MorningstarJune Monthly Letter - Strong Pipeline and Preparations for An Intensive AutumniZafe Group reported a strong pipeline in June, with six Swedish municipalities planning Dosell start-ups in August and September. Manufacturing delays in the Netherlands are expected to resolve in early July, enabling new unit deliveries from August. The company will pause its monthly letter until September.MorningstariZafe Group's CEO Transfers Shares Privately to Enable Participation in LTIP 2026:IiZafe Group CEO Anders Segerström transferred 900,901 B shares privately to Magnus Gilland to enable participation in the company's LTIP 2026:I program. The transfer does not constitute a new share issue or capital raise. Segerström's holding after the transaction is 2,558,550 B shares.BioSpaceCommuniqué from the Extraordinary General Meeting of iZafe Group ABiZafe Group AB held an Extraordinary General Meeting on March 12, 2026, at its Stockholm office, where shareholders approved a directed issue of up to 39,236,014 class B shares as the second part of a capital raise announced on February 19, 2026. The share issue will raise approximately SEK 19.8 million before transaction costs through the issuance of shares at SEK 0.33 per class B share, increasing the company's share capital by a maximum of SEK 1,961,800.70. Following registration of both parts of the directed share issue, the total number of shares will amount to 430,591,337.MorningstariZafe Group AB has Resolved on a Directed Share Issue of Class B Shares of Approximately SEK 19.8 Million in Order to Accelerate the Pace of Sales and InstallationsiZafe Group AB's Board of Directors has resolved to carry out two directed share issues of approximately 60.1 million class B shares at SEK 0.33 per share, raising approximately SEK 19.8 million before transaction costs. The capital raise, which involves deviation from shareholders' pre-emption rights, is intended to fund approximately seven key recruitments in Sweden and the Netherlands to accelerate the pace of sales and installations of the company's Dosell digital medication management products. The company reported that its Annual Recurring Revenue has grown from approximately SEK 1.7 million at the beginning of 2025 to approximately SEK 10 million at the beginning of 2026, and the Second Issue is subject to approval by an Extraordinary General Meeting planned for March 12, 2026.TradingViewiZafe Group’s Quarterly Report Q4, October–December 2025iZafe Group AB published its Q4 2025 report on February 16 showing net sales of 2,435 TSEK, consisting entirely of recurring license revenues with no hardware sales, marking the company's full transition to a subscription-based business model. The company's annual recurring revenue (ARR) reached approximately 10 MSEK at the beginning of 2026, representing 488% growth year-over-year, with new distribution partnerships established in Iceland and Norway during the quarter. Looking ahead, iZafe Group forecasts ARR to grow 125% to 22.5 MSEK by year-end 2026 as it continues expanding its Nordic and European presence.PharmiWeb.comiZafe Group's Quarterly Report Q4, October-December 2025iZafe Group AB published its Q4 2025 report showing total net sales of 2,435 TSEK, consisting entirely of recurring license revenues with no hardware sales, demonstrating the company's successful transition from a hardware-focused to a subscription-based business model. The company's annual recurring revenue reached approximately 10 MSEK at the beginning of 2026, representing a 488 percent increase year-over-year, in line with previously communicated targets. During the quarter, iZafe Group entered distribution and partnership agreements for its Dosell medication dispensing device in Iceland (with Skand ehf) and Norway (with Vakt og Alarm AS), and launched a new modular external Display and remote care system for Dosell, with ARR forecasted to reach 22.5 MSEK by year-end 2026.TradingViewIZAFE_B: Recurring revenue model established, ARR at 10 MSEK, and Nordic expansion underwayiZafe Group AB (IZAFE_B) has transitioned to a recurring revenue model, reporting Q4 net sales of 2,435 TSEK with annual recurring revenue reaching 10 MSEK, while simultaneously expanding into new Nordic markets. The company acknowledges tight liquidity but states that cost controls and financing measures are in place to address this challenge. Future growth is expected to be supported by new product launches and acquisitions.